1-4 of 4
Se Hoon Park
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

Seung Tae Kim, Simon A. Smith, Peter Mortimer, Arsene-Bienvenu Loembé, Heejin Cho, Kyoung-Mee Kim, Claire Smith, Sophie Willis, Itziar Irurzun-Arana, Alienor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, Jeeyun Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4700–4709.
https://doi.org/10.1158/1078-0432.CCR-21-0251
Published: 01 September 2021
View article titled, Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Open the PDF for Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations

Hye Won Lee, Jason K. Sa, Antonio Gualberto, Catherine Scholz, Hyun Hwan Sung, Byong Chang Jeong, Han Yong Choi, Ghee Young Kwon, Se Hoon Park
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5113–5119.
https://doi.org/10.1158/1078-0432.CCR-20-1246
Published: 01 October 2020
View article titled, A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <em>HRAS</em> Mutations
Open the PDF for A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <em>HRAS</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

Myung-Ju Ahn, Byeong-Bae Park, Jin Seok Ahn, Sang We Kim, Heung-Tae Kim, Jong Seog Lee, Jin Hyung Kang, Jae Yong Cho, Hong Suk Song, Se Hoon Park, Chang Hak Sohn, Sang Won Shin, Jin Hyuck Choi, Chang-Seok Ki, Chan Keum Park, Alison J. Holmes, Pasi A. Jänne, Keunchil Park
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3860–3866.
https://doi.org/10.1158/1078-0432.CCR-07-4608
Published: 16 June 2008
View article titled, Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Open the PDF for Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer? in another window
Journal Articles

Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer

Jinny Park, Byung Bae Park, Jee Youn Kim, Se-Hoon Lee, Soon Il Lee, Ho Young Kim, Jung Han Kim, Se Hoon Park, Kyung-Eun Lee, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4383–4388.
https://doi.org/10.1158/1078-0432.CCR-04-0189
Published: 06 July 2004
View article titled, Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Open the PDF for Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer in another window